Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye

Jpn J Ophthalmol. 2013 Sep;57(5):440-6. doi: 10.1007/s10384-013-0251-y. Epub 2013 Jun 6.

Abstract

Purpose: To evaluate the preliminary long-term efficacy of diquafosol ophthalmic solution for aqueous-deficient dry eye.

Methods: Fifteen patients with mild-to-moderate aqueous-deficient dry eye were enrolled. After a washout period, the patients were treated with 3 % diquafosol ophthalmic solution for 6 months. We assessed 12 subjective dry eye symptoms, corneal and conjunctival staining with fluorescein, tear film break-up time (BUT), lower tear meniscus height measured with anterior-segment optical coherence tomography, Schirmer's testing, and adverse reactions at baseline and 1, 3, and 6 months after the start of treatment.

Results: Treatment with diquafosol ophthalmic solution significantly improved dry eye symptoms, corneal staining, BUT, and tear meniscus height at 1 month and maintained the effectiveness for 6 months. Conjunctival staining significantly improved 3 and 6 months after treatment. No significant adverse reactions developed.

Conclusions: Prolonged use of diquafosol ophthalmic solution for 6 months produced significant improvement both subjectively (dry eye symptom score) and objectively (ocular staining score and tear function tests) for aqueous-deficient dry eye.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Conjunctiva / metabolism
  • Cornea / metabolism
  • Dry Eye Syndromes / drug therapy*
  • Dry Eye Syndromes / physiopathology
  • Female
  • Fluorescein / metabolism
  • Fluorometry
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Polyphosphates / therapeutic use*
  • Purinergic P2Y Receptor Agonists / therapeutic use*
  • Tears / chemistry
  • Tears / physiology
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Uracil Nucleotides / therapeutic use*

Substances

  • Ophthalmic Solutions
  • Polyphosphates
  • Purinergic P2Y Receptor Agonists
  • Uracil Nucleotides
  • diquafosol
  • Fluorescein